ClinicalTrials.gg
CompletedNCT01720524Updated Aug 16, 2021Results posted

A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn

A Phase 3 interventional study of placebo and iv sildenafil in Pulmonary Hypertension, Familial Persistent, of the Newborn, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 42 sites in 12 countries. Open to participants aged 0 Days to 4 Days. Per ClinicalTrials.gov, last updated 2021-08-16.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
59
Allocation
Randomized
Ages
0 Days to 4 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies in Persistent Fetal Circulation Syndrome with a site in United States — 1 open to participants now, 2 under way, none of them phase 3. Persistent Fetal Circulation Syndrome · United States.

Enrollment
4th of 12
59 · median 38
Started
2013
with 1 other
Phase 3
3 of 16
none open now
Registered
12th of 16
by date
Lead sponsor
1 of 16
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 16 studies in Persistent Fetal Circulation Syndrome with a site in United States, this one is the 4th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2013, is one of 3 in phase 3, and was the 12th registered.

Persistent Fetal Circulation Syndrome

40 studies on the registry are indexed under Persistent Fetal Circulation Syndrome; 6 are open to participants now.

Browse Persistent Fetal Circulation Syndrome studies →

Open to participants now

1 of the 16 studies in Persistent Fetal Circulation Syndrome with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 Persistent Fetal Circulation Syndrome studies recruiting now, 2 set no upper age limit and 3 stop at 75 or younger; 5 take children under 18; 1 takes healthy volunteers.

This study: 0 Days to 4 Days · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Persistent Fetal Circulation Syndrome with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate whether IV sildenafil can reduce the time on inhaled nitric oxide treatment and reduce the failure rate of available treatments for persistent pulmonary hypertension of the newborn.

03

Conditions studied

  • Pulmonary Hypertension, Familial Persistent, of the Newborn

Keywords

  • persistent pulmonary hypertension
  • newborn
  • neonates
  • iv sildenafil
  • hypoxic respiratory failure and at risk of persistent pulmonary hypertension of the newborn
04

Who can participate

Ages eligible
0 Days to 4 Days
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Neonates with persistent pulmonary hypertension of the newborn
  • Age \<=96 hours and >=34 weeks gestational age
  • Oxygenation Index >15 and \<60
  • Concurrent treatment with inhaled nitric oxide and >=50% oxygen

Exclusion criteria

Exclusion Criteria:

  • Prior or immediate need for extracorporeal membrane oxygenation or cardiopulmonary resuscitation
  • Expected duration of mechanical ventilation \<48 hours
  • Profound hypoxemia
  • Life-threatening or lethal congenital anomaly
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
59 participants (actual)

Study arms

  • Placebo comparator
    placebo

    iv placebo of normal saline or 10% dextrose

    Drug: placebo

  • Experimental
    sildenafil

    Active study drug

    Drug: iv sildenafil

Interventions

  • Drugplacebo

    IV placebo or 0.9% sodium chloride or 10% dextrose. Infusion rate based on weight.

  • loading dose of 0.1 mg/kg over 30 minutes followed by maintenance dose of 0.03 mg/kg/h. To infuse minimum 48 hours and maximum of 14 days.

    Also known as: revatio

06

What researchers measure

Primary outcomes

  1. Time on Inhaled Nitric Oxide (iNO) Treatment After Initiation of Intravenous (IV) Study Drug For Participants Without Treatment Failure

    Time in days, on iNO treatment, for participants without iNO treatment failure, was calculated 14 days from the initiation of IV study drug or hospital discharge, whichever occurred first. iNO treatment failure was defined as need for additional treatment targeting PPHN, need for extra corporeal membrane oxygenation (ECMO), or death during the study.

    Time frame: 14 days from the initiation of IV study drug or hospital discharge, whichever occurs first (maximum of 14 days)

  2. Treatment Failure Rate

    Treatment failure rate was defined as percentage of participants who needed additional treatment targeting PPHN, needed ECMO, or died during the study.

    Time frame: 14 days from the initiation of IV study drug or hospital discharge, whichever occurs first (maximum of 14 days)

Secondary outcomes

  1. Time From Initiation of Intravenous (IV) Study Drug to Final Weaning of Mechanical Ventilation

    Time in days, from initiation of IV study drug to final weaning of mechanical ventilation among participants achieving final weaning of mechanical ventilation for PPHN was evaluated. Kaplan-Meier method was used for estimation. For participants with mechanical ventilation beyond 336 hours (14 days) from initiation of IV study drug, data was censored at 14 days.

    Time frame: 14 days from the initiation of IV study drug or hospital discharge, whichever occurs first (maximum of 14 days)

  2. Time From Initiation of Intravenous (IV) Study Drug to First Treatment Failure

    Time in days, from initiation of IV study drug to first treatment failure (defined as need for additional treatment targeting PPHN, need for ECMO, or death) for participants with treatment failure was evaluated. Kaplan-Meier method was used for estimation. For participants without treatment failure by the endpoint assessment date, data was censored at the endpoint assessment date.

    Time frame: 14 days from the initiation of IV study drug or hospital discharge, whichever occurs first (maximum of 14 days)

  3. Percentage of Participants With Individual Components of Treatment Failure

    Percentage of participants with individual components of treatment failure (need to start additional treatment targeting PPHN, need to start ECMO, or death) were evaluated. Some participants could have had multiple qualifying events for treatment failure.

    Time frame: 14 days from the initiation of IV study drug or hospital discharge, whichever occurs first (maximum of 14 days)

  4. Change From Baseline in Oxygenation Index (OI) at Hours 6, 12 and 24 Post-Infusion

    Oxygenation index was calculated as the product of fraction of inspired oxygen (FiO2) and mean airway pressure divided by partial pressure of oxygen dissolved in arterial blood (PaO2) \[(FiO2\*mean airway pressure)/PaO2\] measured in centimeter of water per millimeter of mercury (cmH2O/mmHg). FiO2 is the measure of oxygen concentration that is breathed. Mean airway pressure is defined as an average of the airway pressure throughout the respiratory cycle. PaO2 is the measure of oxygen level dissolved in the arterial blood.

    Time frame: Baseline, Hours 6, 12 and 24 after start of infusion

  5. Change From Baseline in Differential Saturation at Hours 6, 12 and 24 Post-Infusion

    Differential oxygenation saturation is a simple way to detect the right-to left shunting at ductus arteriosus using 2 pulse oximeters. It is the difference between pre-ductal and post-ductal sites pulse oxygen saturation (SpO2). Where, pre-duct refers to right upper extremity and post-duct refers to lower limb. Oxygenation saturation is measured as percentage of hemoglobin binding sites occupied by oxygen in the blood.

    Time frame: Baseline, Hours 6, 12 and 24 after start of infusion

  6. Change From Baseline in Ratio of Partial Pressure of Oxygen in Arterial Blood to Fraction of Inspired Oxygen (P/F) at Hours 6, 12 and 24

    The ratio of partial pressure of arterial oxygen to fraction of inspired oxygen is a ratio between the oxygen level in the arterial blood and the oxygen concentration that is breathed. It helps to determine the degree of any problems with how the lungs transfer oxygen to the blood.

    Time frame: Baseline, Hours 6, 12 and 24 after start of infusion

  7. Maximum Plasma Concentration (Cmax) of Sildenafil and Its Metabolite

    Cmax was obtained for Sildenafil and its major metabolite UK-103,320.

    Time frame: Loading dose, Day 1: prior to the start of infusion, 5, 30 minutes after end of loading infusion; Maintenance dose: 48 to 72, 96 to 120 hours during infusion and immediately prior to end of maintenance infusion (up to maximum on Day 14)

  8. Total Plasma Clearance (CL) of Sildenafil and Its Metabolite

    CL is volume of the body fluid/ plasma from which the drug or the metabolite is completely removed per unit time. CL was obtained for Sildenafil and its major metabolite UK-103,320.

    Time frame: Loading dose: prior to the start of infusion, 5, 30 minutes after end of loading infusion on Day 1; Maintenance dose: between 48 to 72, 96 to 120 hours during infusion and immediately prior to end of infusion on Day 1

  9. Central Volume of Distribution (Vc) of Sildenafil and Its Metabolite

    Vc is the hypothetical volume into which a drug or a metabolite initially distributes upon administration. It was determined by using a population-based analysis, non-linear mixed-effects modeling (NONMEM), version 7.4.0. Vc was calculated for Sildenafil and its major metabolite, UK-103,320.

    Time frame: Loading dose: prior to the start of infusion, 5, 30 minutes after end of loading infusion on Day 1; Maintenance dose: between 48 to 72, 96 to 120 hours during infusion and immediately prior to end of infusion on Day 1

  10. Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence in a subject who received study drug without regard to possibility of causal relationship. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically important events. Treatment-emergent are events between first infusion of study drug and up to 31 days after end of study drug infusion (up to 45 days) that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAEs and non-SAEs.

    Time frame: Baseline up to 31 days after end of study drug infusion (up to 45 days)

  11. Number of Treatment-Emergent Adverse Events (AEs) According to Severity

    AE: untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE: AE resulting in any of the following outcomes: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically important events. Treatment-emergent are events between first infusion of study drug and up to 31 days after end of study drug infusion (up to 45 days) that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAEs and non-SAEs. Severity criteria: mild=did not interfere with subject's usual function; moderate=interfered to some extent with participant's usual function and severe=interfered significantly with participant's usual function. Missing baseline severities were imputed as mild.

    Time frame: Baseline up to 31 days after end of study drug infusion (up to 45 days)

  12. Number of Participants With Laboratory Abnormalities

    Criteria for laboratory values: Hematology: hemoglobin, hematocrit, red blood cell count \<0.8\*lower limit of normal (LLN), platelets\<0.5\*LLN, \>1.75\*upper limit of normal (ULN), white blood cells count \<0.6\*LLN, \>1.5\*ULN; Liver function: total and direct bilirubin \>1.5\*ULN, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase \>3.0\*ULN, total protein \<0.8\*LLN, \>1.2\*ULN; Renal function: blood urea nitrogen, creatinine \>1.3\*ULN; Electrolytes: sodium \<0.95\*LLN, \>1.05\*ULN, potassium, chloride, calcium, bicarbonate (venous) \<0.9\*LLN, \>1.1\*ULN.

    Time frame: Up to 14 days from initiation of study drug infusion

  13. Part B: Composite Scores of Cognitive, Language, and Motor Developmental Progress of Participants as Assessed by Bayley Scales of Infant and Toddler Development Third Edition (Bayley-III)

    Bayley-III assesses infant and toddler development across five domains: cognitive, language, motor, social-emotional (SE), and adaptive behavior (AB). Assessments of the cognitive, language, and motor domains conducted using items administered to the child; assessments of the SE and AB domains conducted using the primary caregiver's responses to a questionnaire. Score ranges: cognitive scale 0-91, language scale 0-97 and motor scale 0-132, where higher scores indicated better cognitive function, communication and motor skills respectively. Raw scores of cognitive, language and motor domains were converted to composite scores. Composite scores of cognitive, language and motor developmental scales ranged from a scale of 40 to 160, where higher score indicated stronger skills and abilities. In this outcome measure composite scores for infants and toddlers were reported at month 12 and 24.

    Time frame: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)

  14. Part B: Composite Scores of Social-Emotional and Adaptive Behavior Questionnaire as Assessed by Bayley Scales of Infant and Toddler Development Third Edition (Bayley-III)

    The Bayley-III assesses infant and toddler development across five domains: cognitive, language, motor, social-emotional (SE), and adaptive behavior (AB). Assessments of the cognitive, language, and motor domains conducted using items administered to the child; assessments of the SE and AB domains conducted using the primary caregiver's responses to a questionnaire. The questionnaire comprises the SE scale (35 items) and the AB scale (241 items). Raw scores of SE and AB were converted to composite scores. Composite scores for SE and AB scale ranged from 40 to 160, where higher scores indicated better social-emotional skills and adaptive behavior in child. In this outcome measure composite scores for parent/caregiver were reported at month 24.

    Time frame: Month 24 after end of study treatment in Part A (Day 1 to 14)

  15. Part B: Number of Participants With Eye Movement Disorders as Assessed by Eye Examination

    Standard age-appropriate ophthalmological examinations were used to assess eye movement disorders (presence of amblyopia, strabismus, and nystagmus) at month 12 and 24. In this outcome measure, data have been reported for right and left eye separately. Rows according to eye movement disorder categories at specified time points are reported in this outcome measure, only when there was a non-zero data for at least 1 reporting arm.

    Time frame: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)

  16. Part B: Visual Acuity of Verbal Participants as Assessed by Ophthalmological Assessment

    Standard age-appropriate ophthalmological examinations were used to assess visual acuity (performed differently for children able of verbal interaction) through visual acuity chart (VAC) quantitative, counting finger (CF), hand motion (HM), light perception (LP), no light perception (NLP) and missing at month 12 and 24. In this outcome measure, data have been reported for right and left eye separately. Rows according to visual acuity categories at specified time points are reported in this outcome measure, only when there was a non-zero data for at least 1 reporting arm.

    Time frame: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)

  17. Part B: Visual Acuity of Non-Verbal Participants as Assessed by Ophthalmological Assessment

    Standard age-appropriate ophthalmological examinations were used to assess visual acuity (performed differently for children unable of verbal interaction) through fixates and follows (included central, steady and maintained), light perception (wince to light), no light perception, and missing at month 12 and 24. In this outcome measure, data have been reported for right and left eye separately. Rows according to visual acuity categories at specified time points are reported in this outcome measure, only when there was a non-zero data for at least 1 reporting arm.

    Time frame: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)

  18. Part B: Visual Acuity of Verbal Participants as Assessed by LogMAR Through Visual Acuity Chart

    Standard age-appropriate ophthalmological examinations were used to assess visual acuity (performed differently for children able of verbal interaction) at month 12 and 24. Visual acuity (VA) of verbal children was assessed for each eye using the Snellen method, where logarithm of minimum angle of resolution (logMAR) units were derived from the Snellen ratios. Participants had to read letters from the chart at a distance of 20 feet/6 meter or 4 meter. VA (Snellen ratio) = distance between the chart and participant, divided by distance at which participant was able to see/read chart without impairment; expressed as decimal, logMAR = log10 (1/decimal VA). In this outcome measure, data have been reported for right and left eye separately.

    Time frame: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)

  19. Part B: Visual Status of Participants With Abnormality as Assessed by Eye Examination of the Anterior and Posterior Segments

    Standard age-appropriate ophthalmological examinations were used to assess examination of anterior and posterior chamber for abnormality in lids, conjunctiva, cornea, anterior chamber, lens, iris, pupil, extraocular muscle movement and eye movements at month 12 and 24. In this outcome measure, data have been reported for right and left eye separately. Rows according to visual status categories at specified time points are reported in this outcome measure, only when there was a non-zero data for at least 1 reporting arm.

    Time frame: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)

  20. Part B: Audiological Status of Participants as Assessed by Behavior Hearing Assessment Through Pure Tone Audiometry Test

    Audiological evaluations of participants were recorded and reported using behavior hearing assessment through pure tone audiometry test which includes participants with normal, abnormal, incomplete/inconclusive behavior at month 12 and 24.

    Time frame: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)

  21. Part B: Audiological Status of Participants as Assessed by Bone Conduction Through Pure Tone Audiometry Test

    Audiological evaluations of participants were recorded and reported by bone conduction assessment through pure tone audiometry test which included participants with sensorineural hearing loss, conductive hearing loss, mixed hearing loss, neural, and unspecified at month 12 and 24. Rows according to bone conduction categories at specified time points are reported in this outcome measure, only when there was a non-zero data for at least 1 reporting arm.

    Time frame: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)

  22. Part B: Audiological Status of Participants as Assessed by Air Conduction Via Phones/Headphones Through Pure Tone Audiometry Test

    Audiological evaluations of participants were recorded and reported by air conduction via phones/headphones through pure tone audiometry test which included participants with hearing loss ranged from less than or equal to (\<=) 20 decibel hearing loss (DB HL), 21-40 DB HL, 41-70 DB HL, 71-90 DB HL, greater than (\>) 90 DB HL or no response, and missing at frequencies ranged from 500 Hertz (Hz) to 8000 Hz at month 12 and 24. In this outcome measure, data have been reported for right and left ear separately. Rows according to air conduction categories at specified time points are reported in this outcome measure, only when there was a non-zero data for at least 1 reporting arm.

    Time frame: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)

  23. Part B: Audiological Status of Participants as Assessed by Air Conduction Via Soundfield Through Pure Tone Audiometry Test

    Audiological evaluations of participants were recorded and reported by air conduction via soundfield through pure tone audiometry test which included participants with hearing loss ranged from \<=20 DB HL, 21-40 DB HL, 41-70 DB HL, 71-90 DB HL, \>90 DB HL or no response, and missing at frequencies ranged from 500 Hz to 4000 Hz at month 12 and 24. Rows according to air conduction categories at specified time points are reported in this outcome measure, only when there was a non-zero data for at least 1 reporting arm.

    Time frame: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)

  24. Part B: Audiological Status of Participants as Assessed by Tympanometry Assessment (Peak Pressure) Through Immittance Audiometry Test

    Audiological evaluations of participants were recorded and reported by tympanometry assessment through immittance audiometry test which included participants with peak pressure signs (+) and (-) at month 12 and 24. In this outcome measure, data have been reported for right and left ear separately.

    Time frame: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)

  25. Part B: Audiological Status of Participants as Assessed by Tympanometry Assessment (Static Acoustic Admittance) Through Immittance Audiometry Test

    Audiological evaluations of participants were recorded and reported by tympanometry assessment through immittance audiometry test which included participants with static acoustic admittance at month 12 and 24. In this outcome measure, data have been reported for right and left ear separately.

    Time frame: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)

  26. Part B: Audiological Status of Participants as Assessed by Ipsilateral Stapedial Reflex Through Immittance Audiometry Test

    Audiological evaluations of participants were recorded and reported by ipsilateral stapedial reflex through immittance audiometry test which included participants with presence of ipsilateral stapedial reflex at frequencies ranged from 500 Hz to 2000 Hz at month 12 and 24. Ipsilateral stapedial reflex measures are used to assess the neural pathway surrounding the stapedial reflex, which occurs in response to a loud sound (70 to 90 decibel above threshold). In this outcome measure, data have been reported for right and left ear separately.

    Time frame: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)

  27. Part B: Audiological Status of Participants as Assessed by Transient Evoked Emission Through Otoacoustic Emissions Assessment

    Audiological evaluations of participants were recorded and reported by transient evoked emission through otoacoustic emissions assessment which included participants with presence of transient evoked emissions from frequencies 1000 Hz to 4000 Hz at month 12 and 24. In this outcome measure, data have been reported for right and left ear separately.

    Time frame: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)

  28. Part B: Audiological Status of Participants as Assessed by Distort Product Through Otoacoustic Emissions Assessment

    Audiological evaluations of participants were recorded and reported by distort product through otoacoustic emissions assessment which included participants with presence of distort product at frequencies ranged from 2000 Hz to 8000 Hz at month 12 and 24. Distortion-product otoacoustic emissions (DPOAEs) are generated in the cochlea in response to two tones of a given frequency and sound pressure level presented in the ear canal. Distort product otoacoustic emissions are an objective indicator of normally functioning cochlea outer hair cells. In this outcome measure, data have been reported for right and left ear separately.

    Time frame: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)

  29. Part B: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Deaths

    An AE was any untoward medical occurrence in a participant who received study medication without regard to possibility of causal relationship to it. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/ incapacity; congenital anomaly. AEs included both serious and all non-serious AEs.

    Time frame: up to 24 months after end of study treatment in Part A (maximum up to 26 months)

  30. Part B: Neurological Progress of Participants as Assessed by the Neurology Optimality Score

    The Hammersmith Infant Neurological Examination (HINE) was a standard scoring examination to assess development of cranial nerve; posture; movement; tone; and reflexes and reaction. HINE exam global score is a sum of subset (cranial nerve, posture, movement, tone, reflexes and reactions) scores, ranged from 0 to 78, where higher score represents better outcome. Here, the HINE global scores were reported at month 12 and 24.

    Time frame: Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)

07

Results

Posted Mar 25, 2020

Participant flow

This study was planned in two parts Part A (double-blind phase) and Part B (long-term, non-intervention phase).

Part A
Participant flow — Part A
MilestoneIV SildenafilPlacebo
Started2930
Completed2218
Not completed712
Withdrew: Insufficient clinical response24
Withdrew: Adverse event22
Withdrew: Death21
Withdrew: Lost to follow-up01
Withdrew: Missed 28 day follow-up visit11
Withdrew: Withdrawal by subject01
Withdrew: Other01
Withdrew: Lost to follow-up01
Part B
Participant flow — Part B
MilestoneIV SildenafilPlacebo
Started2726
Completed2217
Not completed59
Withdrew: No longer willing to participate in study14
Withdrew: Other20
Withdrew: Lost to follow-up23
Withdrew: Death02

Outcome measures

PrimaryTime on Inhaled Nitric Oxide (iNO) Treatment After Initiation of Intravenous (IV) Study Drug For Participants Without Treatment Failure

Time in days, on iNO treatment, for participants without iNO treatment failure, was calculated 14 days from the initiation of IV study drug or hospital discharge, whichever occurred first. iNO treatment failure was defined as need for additional treatment targeting PPHN, need for extra corporeal membrane oxygenation (ECMO), or death during the study.

Time frame:
14 days from the initiation of IV study drug or hospital discharge, whichever occurs first (maximum of 14 days)
Reported as:
Least squares mean · days
Time on Inhaled Nitric Oxide (iNO) Treatment After Initiation of Intravenous (IV) Study Drug For Participants Without Treatment Failure
daysIV SildenafilPlacebo
Time on Inhaled Nitric Oxide (iNO) Treatment After Initiation of Intravenous (IV) Study Drug For Participants Without Treatment Failure4.1 (2.58 to 5.58)4.1 (2.70 to 5.50)
Statistical analysis
  • IV Sildenafil vs Placebo · ANCOVA · p = 0.9850 · Least square (ls) mean difference: 0.0 · 95% CI -2.08 to 2.04
PrimaryTreatment Failure Rate

Treatment failure rate was defined as percentage of participants who needed additional treatment targeting PPHN, needed ECMO, or died during the study.

Time frame:
14 days from the initiation of IV study drug or hospital discharge, whichever occurs first (maximum of 14 days)
Reported as:
Number · percentage of participants
Treatment Failure Rate
percentage of participantsIV SildenafilPlacebo
Treatment Failure Rate27.6 (11.3 to 43.9)20.0 (5.7 to 34.3)
Statistical analysis
  • IV Sildenafil vs Placebo · Chi-squared · p = 0.4935 · Difference in percentage: 7.6 · 95% CI -14.1 to 29.3
SecondaryTime From Initiation of Intravenous (IV) Study Drug to Final Weaning of Mechanical Ventilation

Time in days, from initiation of IV study drug to final weaning of mechanical ventilation among participants achieving final weaning of mechanical ventilation for PPHN was evaluated. Kaplan-Meier method was used for estimation. For participants with mechanical ventilation beyond 336 hours (14 days) from initiation of IV study drug, data was censored at 14 days.

Time frame:
14 days from the initiation of IV study drug or hospital discharge, whichever occurs first (maximum of 14 days)
Reported as:
Median · days
Time From Initiation of Intravenous (IV) Study Drug to Final Weaning of Mechanical Ventilation
daysIV SildenafilPlacebo
Time From Initiation of Intravenous (IV) Study Drug to Final Weaning of Mechanical Ventilation8.3 (5.46 to 11.75)7.3 (5.46 to 10.78)
Statistical analysis
  • IV Sildenafil vs Placebo · Log Rank · p = 0.9885
SecondaryTime From Initiation of Intravenous (IV) Study Drug to First Treatment Failure

Time in days, from initiation of IV study drug to first treatment failure (defined as need for additional treatment targeting PPHN, need for ECMO, or death) for participants with treatment failure was evaluated. Kaplan-Meier method was used for estimation. For participants without treatment failure by the endpoint assessment date, data was censored at the endpoint assessment date.

Time frame:
14 days from the initiation of IV study drug or hospital discharge, whichever occurs first (maximum of 14 days)
Reported as:
Median · days
Time From Initiation of Intravenous (IV) Study Drug to First Treatment Failure
daysIV SildenafilPlacebo
Time From Initiation of Intravenous (IV) Study Drug to First Treatment FailureNA (NA to NA)NA (NA to NA)
Statistical analysis
  • IV Sildenafil vs Placebo · Log Rank · p = 0.4910
SecondaryPercentage of Participants With Individual Components of Treatment Failure

Percentage of participants with individual components of treatment failure (need to start additional treatment targeting PPHN, need to start ECMO, or death) were evaluated. Some participants could have had multiple qualifying events for treatment failure.

Time frame:
14 days from the initiation of IV study drug or hospital discharge, whichever occurs first (maximum of 14 days)
Reported as:
Number · percentage of participants
Percentage of Participants With Individual Components of Treatment Failure
percentage of participantsIV SildenafilPlacebo
Additional Treatment Targeting PPHN13.8 (3.9 to 31.7)10.0 (2.1 to 26.5)
ECMO10.3 (2.2 to 27.4)10.0 (2.1 to 26.5)
Death6.9 (0.8 to 22.8)0.0 (0.0 to 11.6)
Statistical analysis
  • IV Sildenafil vs Placebo · Fisher Exact · p = 0.7065 · Difference in percentage: 3.8 · 95% CI -15.2 to 22.9
  • IV Sildenafil vs Placebo · Fisher Exact · p = >0.999 · Difference in percentage: 0.3 · 95% CI -18.5 to 18.5
  • IV Sildenafil vs Placebo · Fisher Exact · p = 0.2373 · Difference in percentage: 6.9 · 95% CI -5.5 to 22.8
SecondaryChange From Baseline in Oxygenation Index (OI) at Hours 6, 12 and 24 Post-Infusion

Oxygenation index was calculated as the product of fraction of inspired oxygen (FiO2) and mean airway pressure divided by partial pressure of oxygen dissolved in arterial blood (PaO2) \[(FiO2\*mean airway pressure)/PaO2\] measured in centimeter of water per millimeter of mercury (cmH2O/mmHg). FiO2 is the measure of oxygen concentration that is breathed. Mean airway pressure is defined as an average of the airway pressure throughout the respiratory cycle. PaO2 is the measure of oxygen level dissolved in the arterial blood.

Time frame:
Baseline, Hours 6, 12 and 24 after start of infusion
Reported as:
Least squares mean · cmH2O/mmHg
Change From Baseline in Oxygenation Index (OI) at Hours 6, 12 and 24 Post-Infusion
cmH2O/mmHgIV SildenafilPlacebo
Change at Hour 6-4.2 (-11.64 to 3.34)-8.0 (-16.63 to 0.57)
Change at Hour 12-4.1 (-10.51 to 2.23)-8.2 (-15.42 to -1.04)
Change at Hour 24-11.6 (-15.40 to -7.83)-9.5 (-13.36 to -5.57)
Statistical analysis
  • IV Sildenafil vs Placebo · ANCOVA · p = 0.4984 · Ls mean difference: 3.9 · 95% CI -7.5 to 15.3
  • IV Sildenafil vs Placebo · ANCOVA · p = 0.3956 · Ls mean difference: 4.1 · 95% CI -5.5 to 13.7
  • IV Sildenafil vs Placebo · ANCOVA · p = 0.4249 · Ls mean difference: -2.2 · 95% CI -7.6 to 3.3
SecondaryChange From Baseline in Differential Saturation at Hours 6, 12 and 24 Post-Infusion

Differential oxygenation saturation is a simple way to detect the right-to left shunting at ductus arteriosus using 2 pulse oximeters. It is the difference between pre-ductal and post-ductal sites pulse oxygen saturation (SpO2). Where, pre-duct refers to right upper extremity and post-duct refers to lower limb. Oxygenation saturation is measured as percentage of hemoglobin binding sites occupied by oxygen in the blood.

Time frame:
Baseline, Hours 6, 12 and 24 after start of infusion
Reported as:
Least squares mean · percentage of hemoglobin
Change From Baseline in Differential Saturation at Hours 6, 12 and 24 Post-Infusion
percentage of hemoglobinIV SildenafilPlacebo
Change at Hour 61.5 (-1.79 to 4.80)0.8 (-3.10 to 4.62)
Change at Hour 12-1.2 (-7.65 to 5.21)6.7 (-0.65 to 14.12)
Change at Hour 241.2 (-7.15 to 9.49)9.3 (-0.40 to 19.08)
Statistical analysis
  • IV Sildenafil vs Placebo · ANCOVA · p = 0.7686 · Ls mean difference: 0.7 · 95% CI -4.3 to 5.8
  • IV Sildenafil vs Placebo · ANCOVA · p = 0.1112 · Ls mean difference: -8.0 · 95% CI -17.8 to 1.9
  • IV Sildenafil vs Placebo · ANCOVA · p = 0.2089 · Ls mean difference: -8.2 · 95% CI -21.2 to 4.8
SecondaryChange From Baseline in Ratio of Partial Pressure of Oxygen in Arterial Blood to Fraction of Inspired Oxygen (P/F) at Hours 6, 12 and 24

The ratio of partial pressure of arterial oxygen to fraction of inspired oxygen is a ratio between the oxygen level in the arterial blood and the oxygen concentration that is breathed. It helps to determine the degree of any problems with how the lungs transfer oxygen to the blood.

Time frame:
Baseline, Hours 6, 12 and 24 after start of infusion
Reported as:
Least squares mean · ratio
Change From Baseline in Ratio of Partial Pressure of Oxygen in Arterial Blood to Fraction of Inspired Oxygen (P/F) at Hours 6, 12 and 24
ratioIV SildenafilPlacebo
Change at Hour 645.3 (17.21 to 73.37)8.1 (-23.48 to 39.60)
Change at Hour 1243.4 (16.76 to 70.13)16.9 (-11.97 to 45.68)
Change at Hour 2494.6 (18.52 to 170.69)14.7 (-67.83 to 97.25)
Statistical analysis
  • IV Sildenafil vs Placebo · ANCOVA · p = 0.0829 · Ls mean difference: 37.2 · 95% CI -5.0 to 79.5
  • IV Sildenafil vs Placebo · ANCOVA · p = 0.1802 · Ls mean difference: 26.6 · 95% CI -12.7 to 65.9
  • IV Sildenafil vs Placebo · ANCOVA · p = 0.1576 · Ls mean difference: 79.9 · 95% CI -32.5 to 192.2
SecondaryMaximum Plasma Concentration (Cmax) of Sildenafil and Its Metabolite

Cmax was obtained for Sildenafil and its major metabolite UK-103,320.

Time frame:
Loading dose, Day 1: prior to the start of infusion, 5, 30 minutes after end of loading infusion; Maintenance dose: 48 to 72, 96 to 120 hours during infusion and immediately prior to end of maintenance infusion (up to maximum on Day 14)
Reported as:
Mean · nanogram per milliliter
Maximum Plasma Concentration (Cmax) of Sildenafil and Its Metabolite
nanogram per milliliterIV Sildenafil
Loading dose: Sildenafil52.64 ± 27.91
Loading dose: UK-1033201.04 ± 1.68
Maintenance dose: Sildenafil78.12 ± 48.63
Maintenance dose: UK-10332021.65 ± 11.57
SecondaryTotal Plasma Clearance (CL) of Sildenafil and Its Metabolite

CL is volume of the body fluid/ plasma from which the drug or the metabolite is completely removed per unit time. CL was obtained for Sildenafil and its major metabolite UK-103,320.

Time frame:
Loading dose: prior to the start of infusion, 5, 30 minutes after end of loading infusion on Day 1; Maintenance dose: between 48 to 72, 96 to 120 hours during infusion and immediately prior to end of infusion on Day 1
Reported as:
Mean · Liters/hour
Total Plasma Clearance (CL) of Sildenafil and Its Metabolite
Liters/hourIV Sildenafil
Sildenafil1.78 ± 0.89
UK-103,3205.05 ± 2.25
SecondaryCentral Volume of Distribution (Vc) of Sildenafil and Its Metabolite

Vc is the hypothetical volume into which a drug or a metabolite initially distributes upon administration. It was determined by using a population-based analysis, non-linear mixed-effects modeling (NONMEM), version 7.4.0. Vc was calculated for Sildenafil and its major metabolite, UK-103,320.

Time frame:
Loading dose: prior to the start of infusion, 5, 30 minutes after end of loading infusion on Day 1; Maintenance dose: between 48 to 72, 96 to 120 hours during infusion and immediately prior to end of infusion on Day 1
Reported as:
Mean · Liters
Central Volume of Distribution (Vc) of Sildenafil and Its Metabolite
LitersIV Sildenafil
Sildenafil8.76 ± 1.8
UK-103,32015.96 ± 11.20
SecondaryNumber of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a subject who received study drug without regard to possibility of causal relationship. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically important events. Treatment-emergent are events between first infusion of study drug and up to 31 days after end of study drug infusion (up to 45 days) that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAEs and non-SAEs.

Time frame:
Baseline up to 31 days after end of study drug infusion (up to 45 days)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsIV SildenafilPlacebo
AEs2219
SAEs72
SecondaryNumber of Treatment-Emergent Adverse Events (AEs) According to Severity

AE: untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE: AE resulting in any of the following outcomes: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically important events. Treatment-emergent are events between first infusion of study drug and up to 31 days after end of study drug infusion (up to 45 days) that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAEs and non-SAEs. Severity criteria: mild=did not interfere with subject's usual function; moderate=interfered to some extent with participant's usual function and severe=interfered significantly with participant's usual function. Missing baseline severities were imputed as mild.

Time frame:
Baseline up to 31 days after end of study drug infusion (up to 45 days)
Reported as:
Number · events
Number of Treatment-Emergent Adverse Events (AEs) According to Severity
eventsIV SildenafilPlacebo
Mild4942
Moderate2924
Severe1217
SecondaryNumber of Participants With Laboratory Abnormalities

Criteria for laboratory values: Hematology: hemoglobin, hematocrit, red blood cell count \<0.8\*lower limit of normal (LLN), platelets\<0.5\*LLN, \>1.75\*upper limit of normal (ULN), white blood cells count \<0.6\*LLN, \>1.5\*ULN; Liver function: total and direct bilirubin \>1.5\*ULN, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase \>3.0\*ULN, total protein \<0.8\*LLN, \>1.2\*ULN; Renal function: blood urea nitrogen, creatinine \>1.3\*ULN; Electrolytes: sodium \<0.95\*LLN, \>1.05\*ULN, potassium, chloride, calcium, bicarbonate (venous) \<0.9\*LLN, \>1.1\*ULN.

Time frame:
Up to 14 days from initiation of study drug infusion
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities
ParticipantsIV SildenafilPlacebo
Number of Participants With Laboratory Abnormalities2722
SecondaryPart B: Composite Scores of Cognitive, Language, and Motor Developmental Progress of Participants as Assessed by Bayley Scales of Infant and Toddler Development Third Edition (Bayley-III)

Bayley-III assesses infant and toddler development across five domains: cognitive, language, motor, social-emotional (SE), and adaptive behavior (AB). Assessments of the cognitive, language, and motor domains conducted using items administered to the child; assessments of the SE and AB domains conducted using the primary caregiver's responses to a questionnaire. Score ranges: cognitive scale 0-91, language scale 0-97 and motor scale 0-132, where higher scores indicated better cognitive function, communication and motor skills respectively. Raw scores of cognitive, language and motor domains were converted to composite scores. Composite scores of cognitive, language and motor developmental scales ranged from a scale of 40 to 160, where higher score indicated stronger skills and abilities. In this outcome measure composite scores for infants and toddlers were reported at month 12 and 24.

Time frame:
Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Reported as:
Mean · units on a scale
Part B: Composite Scores of Cognitive, Language, and Motor Developmental Progress of Participants as Assessed by Bayley Scales of Infant and Toddler Development Third Edition (Bayley-III)
units on a scaleIV SildenafilPlacebo
Cognitive Development: Month 1297.5 ± 16.1494.5 ± 14.18
Cognitive Development: Month 2497.4 ± 18.1297.3 ± 14.95
Language Development: Month 1299.5 ± 16.8694.7 ± 10.25
Language Development: Month 2496.7 ± 21.9195.8 ± 17.70
Motor Development: Month 1293.1 ± 16.1088.2 ± 14.61
Motor Development: Month 2499.0 ± 19.59105.3 ± 24.00
SecondaryPart B: Composite Scores of Social-Emotional and Adaptive Behavior Questionnaire as Assessed by Bayley Scales of Infant and Toddler Development Third Edition (Bayley-III)

The Bayley-III assesses infant and toddler development across five domains: cognitive, language, motor, social-emotional (SE), and adaptive behavior (AB). Assessments of the cognitive, language, and motor domains conducted using items administered to the child; assessments of the SE and AB domains conducted using the primary caregiver's responses to a questionnaire. The questionnaire comprises the SE scale (35 items) and the AB scale (241 items). Raw scores of SE and AB were converted to composite scores. Composite scores for SE and AB scale ranged from 40 to 160, where higher scores indicated better social-emotional skills and adaptive behavior in child. In this outcome measure composite scores for parent/caregiver were reported at month 24.

Time frame:
Month 24 after end of study treatment in Part A (Day 1 to 14)
Reported as:
Mean · units on a scale
Part B: Composite Scores of Social-Emotional and Adaptive Behavior Questionnaire as Assessed by Bayley Scales of Infant and Toddler Development Third Edition (Bayley-III)
units on a scaleIV SildenafilPlacebo
Social-Emotional Development104.5 ± 21.40112.5 ± 18.13
Adaptive Behavior Development91.6 ± 15.6698.3 ± 12.44
SecondaryPart B: Number of Participants With Eye Movement Disorders as Assessed by Eye Examination

Standard age-appropriate ophthalmological examinations were used to assess eye movement disorders (presence of amblyopia, strabismus, and nystagmus) at month 12 and 24. In this outcome measure, data have been reported for right and left eye separately. Rows according to eye movement disorder categories at specified time points are reported in this outcome measure, only when there was a non-zero data for at least 1 reporting arm.

Time frame:
Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Reported as:
Count of participants · Participants
Part B: Number of Participants With Eye Movement Disorders as Assessed by Eye Examination
ParticipantsIV SildenafilPlacebo
Strabismus Present, Right Eye: Month 1201
Strabismus Present, Left Eye: Month 1201
Strabismus Present, Right Eye: Month 2410
Strabismus Present, Left Eye: Month 2410
Nystagmus Present, Left Eye: Month 2401
SecondaryPart B: Visual Acuity of Verbal Participants as Assessed by Ophthalmological Assessment

Standard age-appropriate ophthalmological examinations were used to assess visual acuity (performed differently for children able of verbal interaction) through visual acuity chart (VAC) quantitative, counting finger (CF), hand motion (HM), light perception (LP), no light perception (NLP) and missing at month 12 and 24. In this outcome measure, data have been reported for right and left eye separately. Rows according to visual acuity categories at specified time points are reported in this outcome measure, only when there was a non-zero data for at least 1 reporting arm.

Time frame:
Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Reported as:
Count of participants · Participants
Part B: Visual Acuity of Verbal Participants as Assessed by Ophthalmological Assessment
ParticipantsIV SildenafilPlacebo
VAC Quantitative, Right Eye: Month 1221
HM, Right Eye: Month 1202
LP, Right Eye: Month 1210
Missing, Right Eye: Month 121311
VAC Quantitative, Left Eye: Month 1221
HM, Left Eye: Month 1202
LP, Left Eye: Month 1210
Missing, Left Eye: Month 121311
VAC Quantitative, Right Eye: Month 2465
HM, Right Eye: Month 2410
Missing, Right Eye: Month 2457
VAC Quantitative, Left Eye: Month 2465
Missing, Left Eye: Month 2467
SecondaryPart B: Visual Acuity of Non-Verbal Participants as Assessed by Ophthalmological Assessment

Standard age-appropriate ophthalmological examinations were used to assess visual acuity (performed differently for children unable of verbal interaction) through fixates and follows (included central, steady and maintained), light perception (wince to light), no light perception, and missing at month 12 and 24. In this outcome measure, data have been reported for right and left eye separately. Rows according to visual acuity categories at specified time points are reported in this outcome measure, only when there was a non-zero data for at least 1 reporting arm.

Time frame:
Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Reported as:
Count of participants · Participants
Part B: Visual Acuity of Non-Verbal Participants as Assessed by Ophthalmological Assessment
ParticipantsIV SildenafilPlacebo
Fixates and Follows, Right Eye: Month 121513
Light Perception, Right Eye: Month 1201
Missing, Right Eye: Month 1210
Fixates and Follows, Left Eye: Month 121513
Light Perception, Left Eye: Month 1201
Missing, Left Eye: Month 1210
Fixates and Follows, Right Eye: Month 2459
Missing, Right Eye: Month 2473
Fixates and Follows, Left Eye: Month 2459
Missing, Left Eye: Month 2473
SecondaryPart B: Visual Acuity of Verbal Participants as Assessed by LogMAR Through Visual Acuity Chart

Standard age-appropriate ophthalmological examinations were used to assess visual acuity (performed differently for children able of verbal interaction) at month 12 and 24. Visual acuity (VA) of verbal children was assessed for each eye using the Snellen method, where logarithm of minimum angle of resolution (logMAR) units were derived from the Snellen ratios. Participants had to read letters from the chart at a distance of 20 feet/6 meter or 4 meter. VA (Snellen ratio) = distance between the chart and participant, divided by distance at which participant was able to see/read chart without impairment; expressed as decimal, logMAR = log10 (1/decimal VA). In this outcome measure, data have been reported for right and left eye separately.

Time frame:
Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Reported as:
Mean · LogMAR
Part B: Visual Acuity of Verbal Participants as Assessed by LogMAR Through Visual Acuity Chart
LogMARIV SildenafilPlacebo
Right Eye: Month 120.45 ± 0.3940.57 ± 0.513
Left Eye: Month 120.47 ± 0.3720.57 ± 0.513
Right Eye: Month 240.20 ± 0.1550.28 ± 0.299
Left Eye: Month 240.20 ± 0.1550.35 ± 0.409
SecondaryPart B: Visual Status of Participants With Abnormality as Assessed by Eye Examination of the Anterior and Posterior Segments

Standard age-appropriate ophthalmological examinations were used to assess examination of anterior and posterior chamber for abnormality in lids, conjunctiva, cornea, anterior chamber, lens, iris, pupil, extraocular muscle movement and eye movements at month 12 and 24. In this outcome measure, data have been reported for right and left eye separately. Rows according to visual status categories at specified time points are reported in this outcome measure, only when there was a non-zero data for at least 1 reporting arm.

Time frame:
Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Reported as:
Count of participants · Participants
Part B: Visual Status of Participants With Abnormality as Assessed by Eye Examination of the Anterior and Posterior Segments
ParticipantsIV SildenafilPlacebo
Anterior Segment (Lids), Right Eye: Month 1201
Anterior Segment (Lids), Left Eye: Month 1201
Anterior Segment (Extraocular muscle movements), Right Eye: Month 2410
Anterior Segment (Extraocular muscle movements), Left Eye: Month 2410
SecondaryPart B: Audiological Status of Participants as Assessed by Behavior Hearing Assessment Through Pure Tone Audiometry Test

Audiological evaluations of participants were recorded and reported using behavior hearing assessment through pure tone audiometry test which includes participants with normal, abnormal, incomplete/inconclusive behavior at month 12 and 24.

Time frame:
Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Reported as:
Count of participants · Participants
Part B: Audiological Status of Participants as Assessed by Behavior Hearing Assessment Through Pure Tone Audiometry Test
ParticipantsIV SildenafilPlacebo
Normal Behavioral Assessment: Month 12118
Abnormal Behavioral Assessment: Month 1214
Incomplete/Inconclusive Behavioral Assessment: Month 1240
Normal Behavioral Assessment: Month 24138
Abnormal Behavioral Assessment: Month 2402
Incomplete/Inconclusive Behavioral Assessment: Month 2432
SecondaryPart B: Audiological Status of Participants as Assessed by Bone Conduction Through Pure Tone Audiometry Test

Audiological evaluations of participants were recorded and reported by bone conduction assessment through pure tone audiometry test which included participants with sensorineural hearing loss, conductive hearing loss, mixed hearing loss, neural, and unspecified at month 12 and 24. Rows according to bone conduction categories at specified time points are reported in this outcome measure, only when there was a non-zero data for at least 1 reporting arm.

Time frame:
Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Reported as:
Count of participants · Participants
Part B: Audiological Status of Participants as Assessed by Bone Conduction Through Pure Tone Audiometry Test
ParticipantsIV SildenafilPlacebo
Conductive Hearing Loss: Month 1201
Unspecified: Month 1211
Conductive Hearing Loss: Month 24—1
SecondaryPart B: Audiological Status of Participants as Assessed by Air Conduction Via Phones/Headphones Through Pure Tone Audiometry Test

Audiological evaluations of participants were recorded and reported by air conduction via phones/headphones through pure tone audiometry test which included participants with hearing loss ranged from less than or equal to (\<=) 20 decibel hearing loss (DB HL), 21-40 DB HL, 41-70 DB HL, 71-90 DB HL, greater than (\>) 90 DB HL or no response, and missing at frequencies ranged from 500 Hertz (Hz) to 8000 Hz at month 12 and 24. In this outcome measure, data have been reported for right and left ear separately. Rows according to air conduction categories at specified time points are reported in this outcome measure, only when there was a non-zero data for at least 1 reporting arm.

Time frame:
Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Reported as:
Count of participants · Participants
Part B: Audiological Status of Participants as Assessed by Air Conduction Via Phones/Headphones Through Pure Tone Audiometry Test
ParticipantsIV SildenafilPlacebo
Right Ear, 500 Hz, <=20 DB HL: Month 1234
Right Ear, 500 Hz, 21 - 40 DB HL: Month 1221
Right Ear, 1000 Hz, <=20 DB HL: Month 1245
Right Ear, 1000 Hz, 21 - 40 DB HL: Month 1210
Right Ear, 2000 Hz, <=20 DB HL: Month 1234
Right Ear, 2000 Hz, 21 - 40 DB HL: Month 1220
Right Ear, 4000 Hz, <=20 DB HL: Month 1245
Right Ear, 4000 Hz, 21 - 40 DB HL: Month 1210
Right Ear, 8000 Hz, <=20 DB HL: Month 1234
Right Ear, 8000 Hz, Missing: Month 1220
Left Ear, 500 Hz, <=20 DB HL: Month 1233
Left Ear, 500 Hz, 21 - 40 DB HL: Month 1221
Left Ear, 1000 Hz, <=20 DB HL: Month 1235
Left Ear, 1000 Hz, 21 - 40 DB HL: Month 1220
Left Ear, 2000 Hz, <=20 DB HL: Month 1234
Left Ear, 2000 Hz, 21 - 40 DB HL: Month 1220
Left Ear, 4000 Hz, <=20 DB HL: Month 1245
Left Ear, 4000 Hz, 21 - 40 DB HL: Month 1210
Left Ear, 8000 Hz, <=20 DB HL: Month 1234
Left Ear, 8000 Hz, Missing: Month 1221
Right Ear, 500 Hz, <=20 DB HL: Month 2453
Right Ear, 500 Hz, 21-40 DB HL: Month 2420
Right Ear, 1000 Hz, <=20 DB HL: Month 2452
Right Ear, 1000 Hz, 21-40 DB HL: Month 2410
Right Ear, 2000 Hz, <=20 DB HL: Month 2463
Right Ear, 2000 Hz, 21-40 DB HL: Month 2410
Right Ear, 4000 Hz, <=20 DB HL: Month 2473
Right Ear, 8000 Hz, <=20 DB HL: Month 2443
Right Ear, 8000 Hz, 21-40 DB HL: Month 2410
Right Ear, 8000 Hz, Missing: Month 2410
Left Ear, 500 Hz, <=20 DB HL: Month 2463
Left Ear, 500 Hz, 21-40 DB HL: Month 2410
Left Ear, 1000 Hz, <=20 DB HL: Month 2443
Left Ear, 1000 Hz, 21-40 DB HL: Month 2410
Left Ear, 2000 Hz, <=20 DB HL: Month 2462
Left Ear, 2000 Hz, 21-40 DB HL: Month 2410
Left Ear, 4000 Hz, <=20 DB HL: Month 2474
Left Ear, 8000 Hz, <=20 DB HL: Month 2433
Left Ear, 8000 Hz, 21-40 DB HL: Month 2410
Left Ear, 8000 Hz, Missing: Month 2410
SecondaryPart B: Audiological Status of Participants as Assessed by Air Conduction Via Soundfield Through Pure Tone Audiometry Test

Audiological evaluations of participants were recorded and reported by air conduction via soundfield through pure tone audiometry test which included participants with hearing loss ranged from \<=20 DB HL, 21-40 DB HL, 41-70 DB HL, 71-90 DB HL, \>90 DB HL or no response, and missing at frequencies ranged from 500 Hz to 4000 Hz at month 12 and 24. Rows according to air conduction categories at specified time points are reported in this outcome measure, only when there was a non-zero data for at least 1 reporting arm.

Time frame:
Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Reported as:
Count of participants · Participants
Part B: Audiological Status of Participants as Assessed by Air Conduction Via Soundfield Through Pure Tone Audiometry Test
ParticipantsIV SildenafilPlacebo
500 Hz, <=20 DB HL: Month 1262
500 Hz, 21-40 DB HL: Month 1256
500 Hz, 71-90 DB HL: Month 1210
1000 Hz, <=20 DB HL: Month 1293
1000 Hz, 21-40 DB HL: Month 1215
1000 Hz, 71-90 DB HL: Month 1210
2000 Hz, <=20 DB HL: Month 1272
2000 Hz, 21-40 DB HL: Month 1234
2000 Hz, Missing: Month 1210
4000 Hz, <=20 DB HL: Month 1264
4000 Hz, 21-40 DB HL: Month 1244
4000 Hz, 71-90 DB HL: Month 1210
500 Hz, <=20 DB HL: Month 2462
500 Hz, 21-40 DB HL: Month 2425
1000 Hz, <=20 DB HL: Month 2466
1000 Hz, 21-40 DB HL: Month 2443
2000 Hz, <=20 DB HL: Month 2463
2000 Hz, 21-40 DB HL: Month 2424
4000 Hz, <=20 DB HL: Month 2454
4000 Hz, 21-40 DB HL: Month 2443
SecondaryPart B: Audiological Status of Participants as Assessed by Tympanometry Assessment (Peak Pressure) Through Immittance Audiometry Test

Audiological evaluations of participants were recorded and reported by tympanometry assessment through immittance audiometry test which included participants with peak pressure signs (+) and (-) at month 12 and 24. In this outcome measure, data have been reported for right and left ear separately.

Time frame:
Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Reported as:
Mean · decapascals
Part B: Audiological Status of Participants as Assessed by Tympanometry Assessment (Peak Pressure) Through Immittance Audiometry Test
decapascalsIV SildenafilPlacebo
Peak Pressure for Sign (+), Right Ear: Month 1251.89 ± 63.02427.33 ± 26.539
Peak Pressure for Sign (+), Left Ear: Month 125.07 ± 4.90073.75 ± 28.987
Peak Pressure for Sign (+), Right Ear: Month 2444.00 ± 46.13033.50 ± 44.125
Peak Pressure for Sign (+), Left Ear: Month 2442.71 ± 50.11235.00 ± 46.578
Peak Pressure for Sign (-), Right Ear: Month 12149.3 ± 144.3467.75 ± 57.350
Peak Pressure for Sign (-), Left Ear: Month 1279.89 ± 64.36746.80 ± 46.912
Peak Pressure for Sign (-), Right Ear: Month 2498.00 ± 55.68583.67 ± 107.38
Peak Pressure for Sign (-), Left Ear: Month 24102.2 ± 84.781135.0 ± 70.711
SecondaryPart B: Audiological Status of Participants as Assessed by Tympanometry Assessment (Static Acoustic Admittance) Through Immittance Audiometry Test

Audiological evaluations of participants were recorded and reported by tympanometry assessment through immittance audiometry test which included participants with static acoustic admittance at month 12 and 24. In this outcome measure, data have been reported for right and left ear separately.

Time frame:
Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Reported as:
Mean · millimho
Part B: Audiological Status of Participants as Assessed by Tympanometry Assessment (Static Acoustic Admittance) Through Immittance Audiometry Test
millimhoIV SildenafilPlacebo
Right Ear: Month 120.241 ± 0.14030.403 ± 0.1691
Left Ear: Month 120.364 ± 0.15130.330 ± 0.1595
Right Ear: Month 240.273 ± 0.07840.400 ± 0.1321
Left Ear: Month 240.295 ± 0.06910.585 ± 0.5558
SecondaryPart B: Audiological Status of Participants as Assessed by Ipsilateral Stapedial Reflex Through Immittance Audiometry Test

Audiological evaluations of participants were recorded and reported by ipsilateral stapedial reflex through immittance audiometry test which included participants with presence of ipsilateral stapedial reflex at frequencies ranged from 500 Hz to 2000 Hz at month 12 and 24. Ipsilateral stapedial reflex measures are used to assess the neural pathway surrounding the stapedial reflex, which occurs in response to a loud sound (70 to 90 decibel above threshold). In this outcome measure, data have been reported for right and left ear separately.

Time frame:
Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Reported as:
Count of participants · Participants
Part B: Audiological Status of Participants as Assessed by Ipsilateral Stapedial Reflex Through Immittance Audiometry Test
ParticipantsIV SildenafilPlacebo
500 Hz, Right Ear: Month 1251
500 Hz, Left Ear: Month 1261
1000 Hz, Right Ear: Month 1251
1000 Hz, Left Ear: Month 1261
2000 Hz, Right Ear: Month 1251
2000 Hz, Left Ear: Month 1261
500 Hz, Right Ear: Month 2442
500 Hz, Left Ear: Month 2442
1000 Hz, Right Ear: Month 2442
1000 Hz, Left Ear: Month 2452
2000 Hz, Right Ear: Month 2442
2000 Hz, Left Ear: Month 2442
SecondaryPart B: Audiological Status of Participants as Assessed by Transient Evoked Emission Through Otoacoustic Emissions Assessment

Audiological evaluations of participants were recorded and reported by transient evoked emission through otoacoustic emissions assessment which included participants with presence of transient evoked emissions from frequencies 1000 Hz to 4000 Hz at month 12 and 24. In this outcome measure, data have been reported for right and left ear separately.

Time frame:
Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Reported as:
Count of participants · Participants
Part B: Audiological Status of Participants as Assessed by Transient Evoked Emission Through Otoacoustic Emissions Assessment
ParticipantsIV SildenafilPlacebo
1000 Hz, Right Ear: Month 1232
1000 Hz, Left Ear: Month 1221
1500 Hz, Right Ear: Month 1232
1500 Hz, Left Ear: Month 1222
2000 Hz, Right Ear: Month 1252
2000 Hz, Left Ear: Month 1252
3000 Hz, Right Ear: Month 1242
3000 Hz, Left Ear: Month 1242
4000 Hz, Right Ear: Month 1262
4000 Hz, Left Ear: Month 1253
1000 Hz, Right Ear: Month 2432
1000 Hz, Left Ear: Month 2422
1500 Hz, Right Ear: Month 2423
1500 Hz, Left Ear: Month 2423
2000 Hz, Right Ear: Month 2473
2000 Hz, Left Ear: Month 2463
3000 Hz, Right Ear: Month 2463
3000 Hz, Left Ear: Month 2443
4000 Hz, Right Ear: Month 2473
4000 Hz, Left Ear: Month 2453
SecondaryPart B: Audiological Status of Participants as Assessed by Distort Product Through Otoacoustic Emissions Assessment

Audiological evaluations of participants were recorded and reported by distort product through otoacoustic emissions assessment which included participants with presence of distort product at frequencies ranged from 2000 Hz to 8000 Hz at month 12 and 24. Distortion-product otoacoustic emissions (DPOAEs) are generated in the cochlea in response to two tones of a given frequency and sound pressure level presented in the ear canal. Distort product otoacoustic emissions are an objective indicator of normally functioning cochlea outer hair cells. In this outcome measure, data have been reported for right and left ear separately.

Time frame:
Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Reported as:
Count of participants · Participants
Part B: Audiological Status of Participants as Assessed by Distort Product Through Otoacoustic Emissions Assessment
ParticipantsIV SildenafilPlacebo
2000 Hz, Right Ear: Month 1244
2000 Hz, Left Ear: Month 1253
3000 Hz, Right Ear: Month 1254
3000 Hz, Left Ear: Month 1253
4000 Hz, Right Ear: Month 1254
4000 Hz, Left Ear: Month 1253
6000 Hz, Right Ear: Month 1244
6000 Hz, Left Ear: Month 1254
8000 Hz, Right Ear: Month 1242
8000 Hz, Left Ear: Month 1252
2000 Hz, Right Ear: Month 2447
2000 Hz, Left Ear: Month 2446
3000 Hz, Right Ear: Month 2475
3000 Hz, Left Ear: Month 2465
4000 Hz, Right Ear: Month 2465
4000 Hz, Left Ear: Month 2465
6000 Hz, Right Ear: Month 2446
6000 Hz, Left Ear: Month 2456
8000 Hz, Right Ear: Month 2432
8000 Hz, Left Ear: Month 2442
SecondaryPart B: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Deaths

An AE was any untoward medical occurrence in a participant who received study medication without regard to possibility of causal relationship to it. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/ incapacity; congenital anomaly. AEs included both serious and all non-serious AEs.

Time frame:
up to 24 months after end of study treatment in Part A (maximum up to 26 months)
Reported as:
Count of participants · Participants
Part B: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Deaths
ParticipantsIV SildenafilPlacebo
AEs1717
SAEs96
Deaths02
SecondaryPart B: Neurological Progress of Participants as Assessed by the Neurology Optimality Score

The Hammersmith Infant Neurological Examination (HINE) was a standard scoring examination to assess development of cranial nerve; posture; movement; tone; and reflexes and reaction. HINE exam global score is a sum of subset (cranial nerve, posture, movement, tone, reflexes and reactions) scores, ranged from 0 to 78, where higher score represents better outcome. Here, the HINE global scores were reported at month 12 and 24.

Time frame:
Month 12 and 24 after end of study treatment in Part A (Day 1 to 14)
Reported as:
Mean · units on a scale
Part B: Neurological Progress of Participants as Assessed by the Neurology Optimality Score
units on a scaleIV SildenafilPlacebo
Neurological Exam Global Score: Month 1269.9 ± 14.9775.6 ± 3.45
Neurological Exam Global Score: Month 2465.6 ± 19.7176.5 ± 2.42

Adverse events

Collected over Part A: Baseline up to 31 days after end of study drug infusion (up to 45 days); Part B: up to 24 months after end of study treatment in Part A (maximum up to 26 months). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: IV Sildenafil2/29 (6.9%)7/29 (24.1%)20/29 (69%)
Part A: Placebo1/30 (3.3%)2/30 (6.7%)19/30 (63.3%)
Part B: IV Sildenafil0/27 (0%)9/27 (33.3%)14/27 (51.9%)
Part B: Placebo2/26 (7.7%)6/26 (23.1%)15/26 (57.7%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventPart A: IV SildenafilPart A: PlaceboPart B: IV SildenafilPart B: Placebo
Respiratory syncytial virus infectionInfections and infestations0/290/302/273/26
PneumoniaInfections and infestations0/290/302/270/26
SeizureNervous system disorders1/290/300/271/26
Respiratory failureRespiratory, thoracic and mediastinal disorders1/290/300/271/26
Viral upper respiratory tract infectionRespiratory, thoracic and mediastinal disorders0/290/300/271/26
Pulmonary hypertension crisisRespiratory, thoracic and mediastinal disorders0/290/300/271/26
Oxygen saturation decreasedInvestigations0/290/300/271/26
Congenital heart diseaseCongenital, familial and genetic disorders0/290/300/271/26
Lung disorderRespiratory, thoracic and mediastinal disorders0/290/300/271/26
Urinary tract infectionInfections and infestations0/290/300/271/26
Most frequent other events
Showing 10 of 153
Most frequent other events
EventPart A: IV SildenafilPart A: PlaceboPart B: IV SildenafilPart B: Placebo
HypokalaemiaMetabolism and nutrition disorders7/290/300/270/26
HypotensionVascular disorders7/293/301/271/26
Ear infectionInfections and infestations0/290/304/270/26
NasopharyngitisInfections and infestations0/290/304/273/26
AnaemiaBlood and lymphatic system disorders4/293/301/272/26
Drug withdrawal syndromeGeneral disorders4/290/300/270/26
PneumothoraxRespiratory, thoracic and mediastinal disorders2/294/300/271/26
Otitis mediaInfections and infestations0/290/301/273/26
BradycardiaCardiac disorders3/291/300/270/26
OedemaGeneral disorders1/293/300/270/26

Baseline characteristics

Safety population included all participants treated with study treatment.

Age, Continuous
Age, Continuous(days)IV SildenafilPlaceboTotal
Mean1.7 ± 0.901.9 ± 0.751.8 ± 0.83
Sex: Female, Male
Sex: Female, Male(Participants)IV SildenafilPlaceboTotal
Female131326
Male161733
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)IV SildenafilPlaceboTotal
Hispanic or Latino303
Not Hispanic or Latino232952
Unknown or Not Reported314
Race (NIH/OMB)
Race (NIH/OMB)(Participants)IV SildenafilPlaceboTotal
American Indian or Alaska Native000
Asian257
Native Hawaiian or Other Pacific Islander000
Black or African American178
White191635
More than one race314
Unknown or Not Reported415
08

Study locations

42 sites
  • Arkansas Children's Hospital
    Little Rock, Arkansas 72202, United States
  • University of California Davis Medical Center
    Sacramento, California 95817, United States
  • University of California Davis
    Sacramento, California 95817, United States
  • University of California Davis Medical Center
    Sacramento, California 95825, United States
  • Children´s National Medical Center
    Washington, District of Columbia 20010, United States
  • Indiana University Health Methodist Hospital
    Indianapolis, Indiana 46202, United States
  • Riley Hospital for Children at IU Health
    Indianapolis, Indiana 46202, United States
  • Sydney and Lois Eskenazi Hospital
    Indianapolis, Indiana 46202, United States
  • Children's Mercy Hospitals & Clinics
    Kansas City, Missouri 64108, United States
  • Duke University Medical Center (DUMC)
    Durham, North Carolina 27710, United States
  • Fairview Hospital
    Cleveland, Ohio 44111, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • OU Follow-Up Program, PREMIEr Clinic, Children's Hospital
    Oklahoma City, Oklahoma 73104, United States
  • OU Neonatal Intensive Care Unit at Children's Hospital
    Oklahoma City, Oklahoma 73104, United States
  • The University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
  • Henry Zarrow Neonatal Intensive Care Unit, Children's Hospital at Saint Francis
    Tulsa, Oklahoma 74136, United States
  • Warren Cancer Research Foundation
    Tulsa, Oklahoma 74136, United States
  • Vanderbilt Children's Hospital
    Nashville, Tennessee 37232, United States
  • Seattle Children's Research Institute
    Seattle, Washington 98101, United States
  • Seattle Childrens Hospital
    Seattle, Washington 98105, United States
  • Universitair Ziekenhuis Antwerpen
    Edegem, 2650, Belgium
  • UZ Gent
    Gent, 9000, Belgium
  • CHUL du CHU de Quebec
    Quebec, G1V 4G2, Canada
  • Aarhus Universitetshospital, Skejby
    Aarhus N, 8200, Denmark
  • Neonatalklinikken Rigshospitalet, 5024
    Copenhagen Ø, 2100, Denmark
  • Centre Hospitalier et Regional de Lille - Hopital Jeanne de Flandre
    Lille, 59037, France
  • Centre Hospitalier et Régional de Lille,
    Lille, 59037, France
  • Hôpital de la Conception Assistance Publique-Hôpitaux de Marseille
    Marseille, 13385, France
  • CHU Robert Debré
    Paris, 75019, France
  • Hopital NECKER - Enfants Malades
    Paris, 75743, France
  • University Hospital of Leipzig
    Leipzig, 04103, Germany
  • Neonatologia Fondazione IRCCS Policlinico San Matteo
    Pavia, 27100, Italy
  • Radboud University Nijmegen Medical Centre
    Nijmegen, 6525 GA, Netherlands
  • Erasmus MC, Sophia Children's hospital
    Rotterdam, 3015 CN, Netherlands
  • Haukeland University Hospital
    Bergen, Haukeland 5000, Norway
  • Hospital Sant Joan de Deu
    Esplugues de Llobregat, Barcelona / Spain 08950, Spain
  • Hospital General Universitario Gregorio Marañon
    Madrid, 28007, Spain
  • Karolinska University Hospital
    Stockholm, 171 76, Sweden
  • St. Michael's Hospital
    Bristol, BS2 8EG, United Kingdom
  • Leicester Royal Infirmary
    Leicester, LE1 5WW, United Kingdom
  • Glenfield Hospital, University Hospitals of Leicester NHS Trust
    Leicester, LE3 9QP, United Kingdom
  • Great Ormond Street Hospital NHS Foundation Trust
    London, WC1N 3JH, United Kingdom
09

References and documents

Publications

  • Pierce CM, Zhang MH, Jonsson B, Iorga D, Cheruvu N, Balagtas CC, Steinhorn RH. Efficacy and Safety of IV Sildenafil in the Treatment of Newborn Infants with, or at Risk of, Persistent Pulmonary Hypertension of the Newborn (PPHN): A Multicenter, Randomized, Placebo-Controlled Trial. J Pediatr. 2021 Oct;237:154-161.e3. doi: 10.1016/j.jpeds.2021.05.051. Epub 2021 May 27. PubMed 34052232 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2013 to primary completion in Oct 2018, 62 months.

Results were first posted in Mar 2020, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2012
First posted
Nov 2, 2012
StartActual
Aug 5, 2013
Primary completionActual
Oct 17, 2018
CompletionActual
Sep 28, 2020
Results first posted
Mar 25, 2020
Last update
Aug 16, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 16, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01720524
Responsible party
Sponsor
First posted
Nov 2, 2012
Start date
Aug 5, 2013
Primary completion
Oct 17, 2018
Completion
Sep 28, 2020
Results posted
Mar 25, 2020
Last update
Aug 16, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sildenafil

Start the discussion